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Background: Cytochrome P450 (CYP) 2C19 is a very important drug metabolizing enzyme. Although the single
nucleotide polymorphisms (SNPs) of CYP2C19 G681A and G636A have been suggested that they may increase the
incidence of cardiovascular events, the relationship between SNPs in CYP2C19 and cerebral ischemic stroke (CIS)
are unclear. The aim of this study was to investigate the correlation between the distribution of G681A and G636A
polymorphisms in CYP2C19 gene and the risk of CIS in Chinese.
Methods: The peripheral blood DNA was extracted from 299 patients with CIS and 295 healthy controls. The
genotyping was conducted using the polymerase chain reaction-restriction fragment length polymorphism. The
sampled sequencing was applied to verify the correctness of genotyping results. Both the genotype and allele
distributions were compared in patients with CIS and healthy controls.
Results: The frequencies of CYP2C19 681AA (11.7% vs. 2.7%; P = 0.000), 636AA (4.0% vs. 0.7%; P = 0.007), 636AG
(7.0% vs. 2.2%; P = 0.038) genotype, CYP2C19 681A (30.9% vs. 20.8%; P = 0.000) and 636A (13.0% vs. 5.8%; P = 0.000)
allele in the CIS group are significantly higher than those in the controls. The frequencies of CYP2C19 681AA (16.7%
vs. 8.6%; P = 0.036), CYP2C19 636AA (7.0% vs. 2.2%; P = 0.038) genotype, CYP2C19 681A (36.4% vs. 27.6%; P = 0.023)
and CYP2C19 636A (17.5% vs.10.3%; P = 0.010) allele in the recurrent stroke group are significantly higher than those in
the first onset group. Multivariate logistic regression analysis of risk factors for cerebral ischemic stroke and recurrent
stroke respectively suggests that the CYP2C19 681AA genotype may be an independent risk factor for CIS (OR = 6.179,
95% CI: 2.285 ~ 16.708; P = 0.000) and recurrent stroke (OR = 2.305, 95% CI: 1.121 ~ 4.743; P = 0.023).
Conclusions: The AA genotype and A allele of CYP2C19 G681A may be related to the occurrence and recurrence of
cerebral ischemic stroke.
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The occurrence of cerebral ischemic stroke is influenced
by eating habits, environment, genetic factors and so on.
Fundamentally, genetic factors involve in a series of key
enzymes and receptors on many metabolic pathways.
Therefore, the study of the genetic risk factor for cerebral
ischemic stroke has become a hot spot currently.
Cytochrome P450(CYP) 2C19 is a very important drug
metabolizing enzyme, which involves in approximately 2%* Correspondence: lixinsci@126.com
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unless otherwise stated.of the clinical drug metabolism. The activity of CYP2C19
enzyme not only exhibits a significant ethnic heterogeneity,
but also has an obvious differences between individuals.
It is believed that the differences are mainly caused by
genetic variations. Many researchers have investigated
the molecular mechanism of CYP2C19 enzyme poly-
morphisms, which include the wild-type CYP2C19*1,
CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CY
P2C19*6, CYP2C19*7, CYP2C19*8, etc. CYP2C19*2 and
CYP2C19*3 are the main variants in CYP2C19, while
others are relatively rare in humans.
Studies have shown that the single nucleotide polymor-
phisms (SNPs) of CYP2C19*2(CYP2C19 G681A, rs4244285)This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the incidence of cardiovascular events [1-3]. Whereas there
are less research about the relationship between SNPs in
CYP2C19 and cerebral ischemic stroke. So we carried out a
case-control study to investigate the relationship between
the distribution of G681A and G636A polymorphisms in
CYP2C19 gene and cerebral ischemic stroke in Chinese Han
population.Methods
Study participants
From May 2011 to March 2013, we recruited 299 patients
with acute cerebral ischemic stroke who were admitted
to the Neurology Department of the second hospital,
Tianjin Medical University, Tianjin, China. All patients
were diagnosed as acute cerebral ischemic stroke, which
was diagnosed by a neurologist according to the diagnos-
tic criteria determined by the guidelines for the primary
prevention of stroke: a guideline for healthcare profes-
sionals from the American Heart Association/American
Stroke Association [4] and confirmed by computed tomo-
graphic (CT) scan and/or conventional magnetic reson-
ance imaging (MRI) of the brain; the time from incidence
to hospitalization was less than seven days. We excluded
patients who had cerebral hemorrhage, transient ischemic
attack (TIA), cerebral venous thrombosis, nervous system
infection, neurodegenerative disease, hepatic and renal
dysfunction, thrombocytopenia and tumor. In addition,
patients were excluded when they took PPI, tricyclic anti-
depressants, antiepileptics and antipsychotics.
Controls enrolled in this study may have high blood
pressure, diabetes, smoking and other vascular risk factors,
excluding history of cerebral ischemic stroke, TIA, atrial
fibrillation, myocardial infarction and venous thrombosis.
All subjects were unrelated Chinese Han. There were
no significant differences in the age and sex distribu-
tions. Informed consent was obtained from all subjects,
and the study was approved by the Ethical Committee of
Tianjin Medical University.Data collection
All subjects underwent a comprehensive medical history,
physical examination and clinical chemistry analysis before
enrollment. Diagnosis of hyperlipidemia was based on
China’s adult dyslipidemia prevention guide [5]. Hyper-
tension was defined as a blood pressure greater than 140/
90 mmHg on at least two independent readings, exclude
secondary hypertension. Diagnosis of ischemic heart disease
according to the WHO diagnostic criteria [6]. Diagnosis
of diabetes mellitus according to the WHO diagnostic
criteria [7], exclude type 1 diabetes mellitus and secondary
diabetes.Genotyping
Blood samples were collected in tubes containing EDTA.
The genomic DNA was extracted using a commercially
available DNA isolation kit (Cwbiotech, Beijing, China)
according to the manufacturer’s instruction.
The primers of CYP2C19*2 and CYP2C19*3 alleles were
designed and synthesized by BGI Beijing Corporation. The
forward primer of 5′- ACC AGA GCT TGG CAT ATT
GTA TCT -3′ and the reverse primer of 5′-GAT TCT
TGG TGT TCT TTT ACT TTC T-3′ were used for the
amplification of the CYP2C19*2 allele. For the CYP2C
19*3 variant, the forward primer was 5′- TTT CAT CCT
GGG CTG TGC TC -3′ and the reverse primer was
5′- TGT ACT TCA GGG CTT GGT CAA T -3′. The
PCR was performed with an initial denaturation at 94°C
for 5 min, followed by 35 cycles of denaturation at 94°C for
30 s, annealing at 60°C for 30 s, elongation at 72°C for 30 s,
and a final extension at 72°C for 10 min. The amplified
products of CYP2C19*2 (192bp) and CYP2C19*3 (234bp)
were respectively digested with SmaI and BamHI fast-
digest restriction enzyme (Takara biotechnology, Dalian).
Samples from each genotype of CYP2C19 were selected
randomly and submitted for direct DNA sequencing which
confirmed the results.
Statistical analysis
Continuous variables were expressed as mean ± standard
deviation (SD) and categorical variables were reported as
counts and percentages. Analyses of t-tests and chi-square
tests were used to test for differences between groups
for continuous and categorical variables, respectively. Mul-
tivariate logistic regression analysis was used to identify
independent predictors of cerebral ischemic stroke. Ana-
lyses were performed using SPSS version 19.0 statistical
software. A value of P < 0.05 (two-sided) was considered
statistically significant. The p value is accurate to three
decimal places when we calculated using SPSS.
Results
A total of 299 patients were enrolled in this study, includ-
ing 177 cases of male, 122 cases of female, the first onset
group were 185 cases, the recurrent stroke group were
114 cases, the mean ages were (67.86 ± 11.472) years. And
a total of 295 controls were enrolled, including 159 males,
136 females, the mean ages were (66.45 ± 12.972) years.
Genotyping
The PCR products of CYP2C19*2 and CYP2C19*3 were
respectively 192bp and 234bp, which were shown in
Figure 1A, and their digested products were respect-
ively showed in Figure 1B and Figure 1C.
As shown in Figure 2, the results of direct DNA se-
quencing verified the correctness of genotyping results.
A B C
Figure 1 The electrophoresis results of the PCR products and digested products of CYP2C19*2 and CYP2C19*3. A: The PCR products of
CYP2C19*2 and CYP2C19*3. Lane M: DNA Marker (50bp~500bp), Lane 1~5: CYP2C19*2, Lane 6~9:CYP2C19*3. B: Digested products of CYP2C19*2.
Lane M: DNA Marker (50bp~500bp), Lane 1,3,4: heterozygous, Lane 2,5,6: wild-type, Lane 7,8: homozygous. C: Digested products of CYP2C19*3.
Lane M: DNA Marker (50bp~500bp), Lane 1: homozygous, Lane 2,4,6,7,8: wild-type, Lane 3,5,9,10: heterozygous.
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Baseline clinical characteristics of the cerebral ischemic
stroke group and the control group are shown in Table 1.
The proportions of hypertension, diabetes, ischemic heart
disease, hyperlipidemia, smoking and drinking in the cere-
bral ischemic stroke group were more than those in the
healthy control group. And the levels of fasting blood-
glucose (FBG), systolic blood pressure and diastolic
blood pressure were significantly higher in the cerebral
ischemic stroke than in the control group, while theA B
C D
Figure 2 Genetic sequencing maps of CYP2C19*2 and CYP2C19*3. The
CYP2C19. Fig. A: wild-type of CYP2C19*2, Fig. B: heterozygous of CYP2C19*2,level of high-density lipoprotein cholesterol (HDL-C)
was significantly lower in the cerebral ischemic stroke
than in the control group. As shown in Table 1, there
were also no significant differences in the levels of total
cholesterol (TC), triglyceride (TG) and LDL-C.
Meanwhile, there were no significant differences in the
proportions of age, gender, smoking, drinking, hyperten-
sion, diabetes, ischemic heart disease, myocardial infarction
and hyperlipidemia in the recurrent stroke group and the
first onset group. There were no significant differences inarrows were pointing to the genetic single nucleotide polymorphisms of
Fig. C: wild-type of CYP2C19*3, Fig. D: heterozygous of CYP2C19*3.
Table 1 Demographic and clinical information of the cerebral ischemic stroke and the control group
Variable The cerebral ischemic stroke (n = 299) The control group (n = 295) t/χ2 value P value
Age (years) 67.86 ± 11.472 66.45 ± 12.972 1.381 0.168
Male (n, %) 177 (59.2) 159 (53.9) 1.697 0.193
Hypertension (n, %) 225 (75.3) 75 (25.4) 147.483 0.000
Diabetes (n, %) 103 (34.4) 21 (7.1) 67.147 0.000
Hyperlipidemia (n, %) 161 (53.8) 122 (41.4) 9.287 0.002
Ischemic heart disease (n, %) 106 (35.5) 36 (12.2) 44.119 0.000
Smoking (n, %) 119 (39.8) 31 (10.5) 67.495 0.000
Drinking (n, %) 72 (24.1) 20 (6.8) 33.956 0.000
Systolic blood pressure (mmHg) 153.01 ± 22.593 127.82 ± 18.146 14.971 0.000
Diastolic blood pressure (mmHg) 86.21 ± 12.644 76.51 ± 9.684 10.489 0.000
Total cholesterol (mmol/L) 5.033 ± 1.366 5.211 ± 1.030 −1.791 0.074
Triglyceride (mmol/L) 1.654 ± 1.116 1.537 ± 1.038 1.322 0.187
High-density lipoprotein cholesterol (mmol/L) 1.113 ± 0.562 1.316 ± 0.452 −4.842 0.000
Low–density lipoprotein cholesterol (mmol/L) 3.157 ± 1.061 3.078 ± 0.815 1.028 0.304
Fasting blood-glucose (mmol/L) 7.504 ± 3.461 5.538 ± 0.980 9.391 0.000
Continuous variables were expressed as mean ± standard deviation (SD) and categorical variables were reported as counts and percentages. The blood pressure is
measured in millimetres of mercury (mm Hg). The blood lipids and glucose concentrations are record in milimolar per litre (mmol/L).
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lipoprotein cholesterol (HDL-C) and FBG in the two
groups, which were shown in Table 2.
Frequency of CYP2C19 genotypes and alleles
The frequency of the major and minor alleles of
CYP2C19*2 and CYP2C19*3 did not deviate significantly
from the Hardy-Weinberg equilibrium neither in theTable 2 Demographic and clinical information of the recurren
Variable The recurrent stroke grou
Age (years, mean ± SD) 69.37 ± 11.132
Male (n, %) 62(54.4)
Hyperlipidemia (n, %) 87(76.3)
Diabetes (n, %) 42(36.8)
Hyperlipidemia (n, %) 65(57.0)
Ischemic heart disease (n, %) 48(42.1)
myocardial infarction (n, %) 4(3.5)
Smoking (n, %) 40(35.1)
Drinking (n, %) 23(20.2)
Systolic blood pressure (mmHg, mean ± SD) 150.99 ± 23.368
Diastolic blood pressure (mmHg, mean ± SD) 85.82 ± 11.937
Total cholesterol (mmol/L, mean ± SD) 4.990 ± 1.619
Triglyceride (mmol/L, mean ± SD) 1.567 ± 0.938
High-density lipoprotein cholesterol
(mmol/L, mean ± SD)
1.056 ± 0.303
Low–density lipoprotein cholesterol
(mmol/L, mean ± SD)
3.148 ± 1.325
Fasting blood-glucose (mmol/L, mean ± SD) 7.733 ± 3.798stroke (χ2 = 1.380, P = 0.502; χ2 = 4.180, P = 0.124), nor
in the control group (χ2 = 1.749, P = 0.417; χ2 = 0.400,
P = 0.819). Frequencies of the CYP2C19*2 and CYP2C19*3
polymorphism in cerebral ischemic stroke patients and
healthy controls are described in Table 3. Frequencies of
CYP2C19 681AA (30.9% vs. 20.8%; P = 0.000), CYP2C19
636AA (4.0% vs. 0.7%; P = 0.007), CYP2C19 636AG (18.1%
vs. 10.2%; P = 0.006) genotype, CYP2C19 681A (30.9% vs.t stroke group and the first onset group
p (n = 114) The first onset group (n = 185) t/χ2 value P value









154.26 ± 22.074 −1.216 0.225
86.46 ± 13.086 −0.427 0.670
5.059 ± 1.188 −0.427 0.670
1.708 ± 1.212 −1.062 0.289
1.148 ± 0.672 −1.386 0.167
3.163 ± 0. 862 −0.119 0.905
7.363 ± 3.239 0.898 0.370
Table 3 Frequencies of the CYP2C19 polymorphism in cerebral ischemic stroke patients and healthy controls (n, %)
Groups
CYP2C19*2 genotypes CYP2C19*2 alleles CYP2C19*3 genotypes CYP2C19*3 alleles
AA AG GG A G AA AG GG A G
Stroke 35 115 149 185 413 12 54 233 78 520
(n = 299) (11.7) (38.5) (49.8) (30.9) (69.1) (4.0) (18.1) (77.9) (13.0) (87.0)
Control 8 107 180 123 467 2 30 263 34 556
(n = 295) (2.7) (36.3) (61.0) (20.8) (79.2) (0.7) (10.2) (89.2) (5.8) (94.2)
χ2 value 17.887 0.304 7.517 15.741 7.178 7.615 13.584 18.437
P value 0.000 0.581 0.006 0.000 0.007 0.006 0.000 0.000
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P = 0.000) allele were significantly higher in the cerebral
ischemic stroke than in the control group.
Frequencies of the CYP2C19*2 and CYP2C19*3 poly-
morphisms in recurrent stroke group and the first onset
group are described in Table 4. Frequencies of CYP2C19
681AA (16.7% vs. 8.6%; P = 0.036), CYP2C19 636AA
(7.0% vs. 2.2%; P = 0.038) genotype, CYP2C19 681A (36.4%
vs. 27.6%; P = 0.023) and CYP2C19 636A (17.5% vs. 10.3%;
P = 0.010) allele were significantly higher in recurrent
stroke group than in the first onset group.
Neurological functions were evaluated immediately with
the US National Institutes of Health nerve function deficit
score (NIHSS) after admission to hospital. Patients were
divided into mild (NIHSS<5), moderate (5 ≤NIHSS ≤ 20)
and severe (NIHSS>20) by rating results [8]. As shown in
Table 5, no significant differences were found in genotype
(χ2 = 4.967, P = 0.291; χ2 = 3.239, P = 0.519) and allele
(χ2 = 0.616, P = 0.735; χ2 = 1.242, P = 0.537) frequencies
of CYP2C19*2 and CYP2C19*3 in the three groups.
Correlation between CYP2C19 genetic polymorphisms
and cerebral ischemic stroke
Multivariate logistic regression analysis showed that the
CYP2C19 681AA genotype was an independent risk fac-
tor for cerebral ischemic stroke (odds ratio (OR) 6.179,
95% confidence interval (CI) 2.285 ~ 16.708; P = 0.000),
which were shown in Table 6, and the CYP2C19 681 AA
genotype was an independent risk factor for recurrent
stroke (OR 2.305, 95% CI 1.121 ~ 4.743; P = 0.023), whileTable 4 Frequencies of the CYP2C19 polymorphism in recurre
Groups
CYP2C19*2 genotypes CYP2C19
AA AG GG A
The recurrent stroke group 19 45 50 83
(n = 114) (16.7) (39.5) (43.9) (36.4)
The first onset group 16 70 99 102
(n = 185) (8.6) (37.8) (53.5) (27.6)
χ2 value 4.387 0.080 2.629 5.1
P value 0.036 0.778 0.105 0.0CYP2C19 636 AA genotype was not associated with the
recurrence of ischemic stroke (P = 0.098). Meanwhile, as
shown in Table 6, hypertension was an independent risk
factor for cerebral ischemic stroke (OR 2.998, 95% CI
1.808 ~ 4.972; P = 0.000).Discussion
CYP2C19 is located within a cluster of cytochrome P450
genes on chromosome 10q24, which contains nine exons
and eight introns. The gene encodes a 490-aa long pro-
tein of approximately 56kDa, which is a member of the
cytochrome P450 superfamily of enzymes. This protein
localizes to the endoplasmic reticulum and is known to
metabolize many xenobiotics, including the anticonvulsive
drug mephenytoin, omeprazole, diazepam and some bar-
biturates. Polymorphism within this gene is associated
with variable ability to metabolize mephenytoin, known as
the poor metabolizer and extensive metabolizer pheno-
types. CYP2C19*2 has been shown to be a G→A transi-
tion at 681bp in exon 5 of wild-type CYP2C19*1. This
variant results in an aberrant splice site and shifts the
reading frame, thereby producing an early-stop codon and
a truncated protein [9]. The CYP2C19*3 involves a G→A
variant at 636bp in exon 4, that also creates a premature
stop codon and a truncated protein [10]. The CYP2C19*2
is the main genetic defect allele of CYP2C19, which
accounts for 75% ~ 85% of poor metabolizers (PM) in both
white and Oriental populations [11]. The second variant
accounts for the remaining defective alleles in Orientalnt stroke group and the first onset group (n, %)
*2 alleles CYP2C19*3 genotypes CYP2C19*3 alleles
G AA AG GG A G
145 8 24 82 40 188
(63.6) (7.0) (21.1) (71.9) (17.5) (82.5)
268 4 30 151 38 332
(72.4) (2.2) (16.2) (81.6) (10.3) (89.7)
55 4.316 1.115 3.852 6.580
23 0.038 0.291 0.050 0.010
Table 5 Frequencies of the CYP2C19 polymorphism in different NIHSS groups in patients
Groups CYP2C19*2 genotypes CYP2C19*2 alleles CYP2C19*3 genotypes CYP2C19*3 alleles
AA AG GG A AA AG GG A G
Mild 19 64 78 102 220 6 34 121 46 276
(n = 161) (11.8) (39.8) (48.4) (31.7) (68.3) (3.7) (21.1) (75.2) (14.3) (85.7)
Moderate 8 37 39 53 115 4 10 70 18 150
(n = 84) (9.5) (44.0) (46.4) (31.5) (68.5) (4.8) (11.9) (83.3) (10.7) (89.3)
Severe 8 14 32 30 78 2 10 42 14 94
(n = 54) (14.8) (25.9) (59.3) (27.8) (72.2) (3.7) (18.5) (77.8) (13.0) (87.0)
χ2 value 0.893 4.806 2.432 0.616 0.170 3.176 2.147 1.242
P value 0.640 0.090 0.296 0.735 0.919 0.204 0.342 0.537
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persons [12].
Yin et al. [13] found that the allele frequencies of
CYP2C19*2 were respectively 29.7%, 32.4% and 18.2%
in Han, Hui and Mongolian, the allele frequencies of
CYP2C19*3 were respectively 7.9%, 10.2% and 11.2% in
Han, Hui and Mongolian. Other literatures [14,15] reported
that the allele frequencies of CYP2C19*2 were 11.1% for
Western Africa, 14.0% for Western Europe and 16.3% for
Northern Europe respectively, and the allele frequencies of
CYP2C19*3 were 0% for Western Africa, 0.2% for Western
Europe and 0.2% for Northern Europe respectively. In our
study, the allele frequencies of CYP2C19*2 and CYP2C19*3
were 25.9% and 9.4% separately. Our result is close with
that in Yin’s report.
Studies have shown that the poor metabolizer gene of
CYP2C19 was related to the occurrence of coronary
heart disease and stroke. Through the research of 654
patients with coronary heart disease, Mao Chen et al. [16]
found that the homozygous CYP2C19*2/*2 genotype was
an independent determinant of adverse vascular events in
Chinese patients with coronary artery disease (CAD). Mega
et al. [17] reported that carriers of a reduced-function
CYP2C19 allele had a higher rate of major adverse cardio-
vascular events than did noncarriers. Actually our researchTable 6 Multivariate logistic regression analysis of
independent risk factor for cerebral ischemic stroke
Independent risk factor 95% CI P value OR value
CYP2C19 681AA 2.285~16.708 0.000 6.179
Hypertension 1.808~4.972 0.000 2.998
Ischemic heart disease 1.366~4.210 0.002 2.398
Diabetes 1.262~4.838 0.008 2.471
Hyperlipidaemia 1.086~3.120 0.023 1.841
Smoking 3.712~11.816 0.000 6.623
Systolic blood pressure 1.036~1.065 0.000 1.051
TC 0.626~0.924 0.006 0.761
FBG 1.257~1.742 0.000 1.480also found that CYP2C19 681AA genotype, CYP2C19
636AA and CYP2C19 636AG genotype were related with
cerebral ischemic stroke. Multivariate logistic regression
analysis showed that the CYP2C19 681AA genotype may
be an independent risk factor for cerebral ischemic stroke.
We postulate that the weak metabolic gene of CYP2C19
may be related to the formation of cerebral artery athero-
sclerosis, thereby causing the incidence of cerebral ischemic
stroke.
Clopidogrel is a prodrug requiring metabolism by
CYP2C19 enzyme, in order to be active, which can play
the role of anti-platelet aggregation. Clopidogrel is widely
used in the secondary prevention of cerebral ischemic
stroke, but its clinical efficacy has individual differences.
Many studies have shown that CYP2C19 polymorphism is
associated with reduced clopidogrel response [18-23]. Our
study suggested that the CYP2C19 681AA genotype was
an independent risk factor for recurrent stroke, since
carriers of a reduced-function CYP2C19 allele had a two-
fold risk with recurrent stroke than did noncarriers.
Conclusion
In summary, the AA genotype and A allele of CYP2C19
G681A may be associated with the occurrence and recur-
rence of cerebral ischemic stroke. In addition, we find that
the genotypes of CYP2C19 G681A and G636A have noth-
ing to do with the severity of cerebral ischemic stroke.
Since our study has limited sample size, further studies in
a large population are needed to confirm these findings.
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